Evidence map›Paper›PMID 38859778›Full record

ReviewMini reviews in medicinal chemistry2024

Insight in Quinazoline-based HDAC Inhibitors as Anti-cancer Agents.

Elena Martino, Shruti Thakur, Arun Kumar, Ashok Kumar Yadav, Donatella Boschi, Deepak Kumar, Marco Lolli

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mini reviews in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elena MartinoDepartment of Science and Drug Technology, University of Turin, via Pietro Giuria 9, Turin, 10125, Italy.ORCID 0009-0006-3697-6832
Shruti ThakurDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, Solan-173229, India.
Arun KumarDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, Solan-173229, India.
Ashok Kumar YadavUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.
Donatella BoschiDepartment of Science and Drug Technology, University of Turin, via Pietro Giuria 9, Turin, 10125, Italy.ORCID 0000-0003-4929-4460
Deepak KumarDepartment of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Himachal Pradesh, Solan-173229, India.ORCID 0000-0003-2241-0054
Marco LolliDepartment of Science and Drug Technology, University of Turin, via Pietro Giuria 9, Turin, 10125, Italy.ORCID 0000-0002-3030-3163

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains a primary cause of death globally, and effective treatments are still limited. While chemotherapy has notably enhanced survival rates, it brings about numerous side effects. Consequently, the ongoing challenge persists in developing potent anti-cancer agents with minimal toxicity. The versatile nature of the quinazoline moiety has positioned it as a pivotal component in the development of various antitumor agents, showcasing its promising role in innovative cancer therapeutics. This concise review aims to reveal the potential of quinazolines in creating anticancer medications that target histone deacetylases (HDACs).

Indexed as

Antineoplastic AgentsHistone Deacetylase InhibitorsHistone DeacetylasesNeoplasmsQuinazolinesAnimalsHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsHistone Deacetylase InhibitorsHistone DeacetylasesQuinazolinesanti-proliferative agentscancerHDAC inhibitorshybrid HDAC inhibitorsmultitarget approach.Quinazoline

Identifiers

PMID38859778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.